A multiplexed Cas13-based assay with point-of-care attributes for simultaneous COVID-19 diagnosis and variant surveillance

Maturada Patchsung, Aimorn Homchan, Kanokpol Aphicho, Surased Suraritdechachai, Thanyapat Wanitchanon, Archiraya Pattama, Khomkrit Sappakhaw, Piyachat Meesawat, Thanakrit Wongsatit, Artittaya Athipanyasilp, Krittapas Jantarug, Niracha Athipanyasilp, Juthamas Buahom, Pat Visanpattanasin, Nootaree Niljianskul, Pimchai Chaiyen, Ruchanok Tinikul, Nuanjun Wichukchinda, Surakameth Mahasirimongkol, Rujipas Sirijatuphat, Nasikarn Angkasekwinai, Michael A. Crone, Paul S. Freemont, Julia Joung, Alim Ladha, Omar O. Abudayyeh, Jonathan S. Gootenberg, Feng Zhang, Claire Chewapreecha, Sittinan Chanarat, Navin Horthongkham, Danaya Pakotiprapha, Chayasith Uttamapinant

Introduction

While the COVID-19 pandemic highlighted the critical role of gold-standard diagnostic technologies like RT-qPCR, it also exposed significant gaps in global testing infrastructure. Standard laboratory-based tests are often slow, expensive, and reliant on sophisticated equipment, making them difficult to scale in resource-limited settings. Furthermore, most existing point-of-care (POC) diagnostics provide only a binary "positive/negative" result, failing to provide the genomic surveillance data necessary to track the emergence and spread of Variants of Concern (VOCs).

To address these challenges, we developed a robust, multiplexed CRISPR-based detection platform. By utilizing orthogonal Cas13 enzymes and locally manufactured reagents, this assay enables simultaneous COVID-19 diagnosis and variant identification in a format suitable for POC deployment. This approach not only bridges the surveillance gap but also addresses supply chain vulnerabilities in low- and middle-income countries (LMICs).

Methodology

Orthogonal CRISPR Detection

The core of the platform relies on the simultaneous use of two distinct CRISPR-Cas13 enzymes: LwaCas13a and PsmCas13b. These enzymes exhibit "collateral cleavage" activity, where they degrade nearby RNA reporters upon target recognition. Crucially, they possess different cleavage preferences—Cas13a targets poly-U probes, while Cas13b targets poly-A probes. This orthogonality allows the assay to detect two different genetic targets in a single reaction tube without signal interference. In our configuration, one enzyme targets a conserved region of the SARS-CoV-2 N gene for general diagnosis, while the other targets specific mutations in the S gene to identify variants such as Delta (B.1.617.2) or Omicron (B.1.1.529).

Isothermal Amplification and Local Manufacturing

To achieve high sensitivity without thermal cyclers, the assay utilizes Reverse-Transcription Recombinase Polymerase Amplification (RT-RPA). RPA operates at a constant temperature (39–42°C), making it ideal for field use. To ensure sustainability and reduce reliance on expensive proprietary reagents, we successfully "home-brewed" the four primary RPA protein components (UvsX, UvsY, Gp32, and Bsu LF). We demonstrated that these locally produced enzymes perform with equivalent efficiency to commercial counterparts, providing a blueprint for decentralized diagnostic manufacturing.

Stabilization and Readout

For ease of deployment, the reagents were stabilized through lyophilization (freeze-drying) using trehalose as a cryoprotectant. This allows for long-term storage and a simple "just-add-sample" workflow. The results can be interpreted via multiple modalities: fluorescence monitored by a smartphone or a simple LED light box, or colorimetric lateral-flow strips for visual interpretation.

Performance and Validation

The assay underwent rigorous validation using synthetic RNA, cultured viral isolates (including ancestral, Alpha, Delta, and Omicron strains), and 136 clinical nasopharyngeal and throat swabs.

Key performance metrics include:

  • High Accuracy: The multiplexed assay demonstrated 100% specificity and 95–97% sensitivity compared to RT-qPCR.
  • Sensitivity: The system achieved a Limit of Detection (LoD) comparable to laboratory tests, reliably detecting the virus in samples with Ct values as high as ~37 (approximately 10 copies/µL).
  • Variant Specificity: The Delta-specific assay showed no cross-reactivity with other strains. While the Omicron-specific assay was slightly less sensitive (LoD ~34 Ct), it maintained high accuracy across clinical samples.
  • Regulatory Milestone: The most sensitive iteration of the freeze-dried assay received full approval from the Thai FDA in September 2021.

Discussion and Future Directions

This platform represents a significant step toward democratizing high-quality molecular diagnostics. By proving that complex, multiplexed CRISPR assays can be produced locally and stored without a cold chain, we offer a sustainable model for pandemic preparedness in LMICs.

While the current protocol primarily utilizes purified RNA, future work will focus on integrating "extraction-free" methods to further simplify the workflow. Additionally, the modular nature of the CRISPR-Cas system allows for rapid reconfiguration; as new variants emerge, the guide RNAs (crRNAs) can be updated with minimal adjustments to the underlying platform. This flexibility ensures that the technology remains relevant for both the ongoing management of COVID-19 and the detection of future infectious disease threats.

Summary updated

Abstract

Abstract Point-of-care (POC) nucleic acid detection technologies are poised to aid gold-standard technologies in controlling the COVID-19 pandemic, yet shortcomings in the capability to perform critically needed complex detection—such as multiplexed detection for viral variant surveillance—may limit their widespread adoption. Herein, we developed a robust multiplexed CRISPR-based detection using LwaCas13a and PsmCas13b to simultaneously diagnose SARS-CoV-2 infection and pinpoint the causative SARS-CoV-2 variant of concern (VOC)— including globally dominant VOCs Delta (B.1.617.2) and Omicron (B.1.1.529)—all while maintaining high levels of accuracy upon the detection of multiple SARS-CoV-2 gene targets. The platform has several attributes suitable for POC use: premixed, freeze-dried reagents for easy use and storage; convenient direct-to-eye or smartphone-based readouts; and a one-pot variant of the multiplexed detection. To reduce reliance on proprietary reagents and enable sustainable use of such a technology in low- and middle-income countries, we locally produced and formulated our own recombinase polymerase amplification reaction and demonstrated its equivalent efficiency to commercial counterparts. Our tool—CRISPR-based detection for simultaneous COVID-19 diagnosis and variant surveillance which can be locally manufactured—may enable sustainable use of CRISPR diagnostics technologies for COVID- 19 and other diseases in POC settings.
BibTeX
@article{patchsung2022multiplexed,
  author = {Maturada Patchsung and Aimorn Homchan and Kanokpol Aphicho and Surased Suraritdechachai and Thanyapat Wanitchanon and Archiraya Pattama and Khomkrit Sappakhaw and Piyachat Meesawat and Thanakrit Wongsatit and Artittaya Athipanyasilp and Krittapas Jantarug and Niracha Athipanyasilp and Juthamas Buahom and Pat Visanpattanasin and Nootaree Niljianskul and Pimchai Chaiyen and Ruchanok Tinikul and Nuanjun Wichukchinda and Surakameth Mahasirimongkol and Rujipas Sirijatuphat and Nasikarn Angkasekwinai and Michael A. Crone and Paul S. Freemont and Julia Joung and Alim Ladha and Omar O. Abudayyeh and Jonathan S. Gootenberg and Feng Zhang and Claire Chewapreecha and Sittinan Chanarat and Navin Horthongkham and Danaya Pakotiprapha and Chayasith Uttamapinant},
  title = {{A multiplexed Cas13-based assay with point-of-care attributes for simultaneous COVID-19 diagnosis and variant surveillance}},
  journal = {The CRISPR Journal},
  year = {2022},
  doi = {10.1089/crispr.2022.0048},
}
Figure